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allergic responses in aspergillus fumigatus
sensitized mice
Zhilong Jiang1, Melane L Fehrenbach1, Giulia Ravaioli1, Blerina Kokalari1, Imre G Redai1, Steven A Sheardown2,
Stephen Wilson3, Colin Macphee4 and Angela Haczku1,5*Abstract
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2)/platelet-activating factor acetylhydrolase (PAF-AH)
has been implicated in the pathogenesis of cardiovascular disease. A therapeutic targeting of this enzyme was
challenged by the concern that increased circulating platelet activating factor (PAF) may predispose to or increase
the severity of the allergic airway response. The aim of this study was to investigate whether Lp-PLA2
gene deficiency increases the risk of PAF and IgE-mediated inflammatory responses in vitro and in vivo using
mouse models.
Methods: Lp-PLA2-/- mice were generated and back crossed to the C57BL/6 background. PAF-AH activity was
measured using a hydrolysis assay in serum and bronchoalveolar lavage (BAL) samples obtained from mice.
Aspergillus fumigatus (Af)-specific serum was prepared for passive allergic sensitization of mice in vivo and mast cells
in vitro. β- hexosaminidase release was studied in bone marrow derived mast cells sensitized with Af-specific serum
or DNP-IgE and challenged with Af or DNP, respectively. Mice were treated with lipopolysaccharide (LPS) and PAF
intratracheally and studied 24 hours later. Mice were sensitized either passively or actively against Af and were
studied 48 hours after a single intranasal Af challenge. Airway responsiveness to methacholine, inflammatory cell
influx in the lung tissue and BAL, immunoglobulin (ELISA) and cytokine (Luminex) profiles were compared between
the wild type (WT) and Lp-PLA2-/- mice.
Results: PAF-AH activity was reduced but not completely abolished in Lp-PLA2-/- serum or by in vitro treatment of
serum samples with a high saturating concentration of the selective Lp-PLA2 inhibitor, SB-435495. PAF inhalation
significantly enhanced airway inflammation of LPS treated WT and Lp-PLA2-/- mice to a similar extent. Sensitized
WT and Lp-PLA2-/- bone-marrow derived mast cells released β-hexosaminidase following stimulation by allergen or
IgE crosslinking to equivalent levels. Wild type and Lp-PLA2-/- mice responded to passive or active allergic
sensitization by significant IgE production, airway inflammation and hyperresponsiveness after Af challenge. BAL cell
influx was not different between these strains while IL-4, IL-5, IL-6 and eotaxin release was attenuated in Lp-PLA2-/-
mice. There were no differences in the amount of total IgE levels in the Af sensitized WT and Lp-PLA2-/- mice.
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Conclusions: We conclude that Lp-PLA2 deficiency in C57BL/6 mice did not result in a heightened airway
inflammation or hyperresponsiveness after PAF/LPS treatment or passive or active allergic sensitization
and challenge.
Keywords: Lp-PLA2, PAF-AH, Knock-out mice, Airway inflammation, IgE, Mast cells, DegranulationIntroduction
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a
45-kDa protein of 441 amino acids encoded by the
pla2g7 gene in humans. In the blood it travels mainly
with low density lipoprotein (LDL) and less than 20% is
associated with high density lipoprotein (HDL). This
enzyme is produced by myeloid derived cells and it
functions to hydrolyze oxidized/polar phospholipids.
Whether Lp-PLA2 is a pro- or anti-inflammatory medi-
ator is the subject of intense debate and numerous stud-
ies involving clinical trials and animal models [1].
Lp-PLA2 is implicated in the development of athero-
sclerosis [2]. A meta-analysis on a total of 79,036 par-
ticipants in 32 prospective studies found that serum
Lp-PLA2 positively correlated with an increased risk of
coronary heart disease and stroke [3]. In atherosclerotic
lesions the main sources of Lp-PLA2 include LDL from
the circulation, and de novo synthesis by the inflamma-
tory cells found in the plaque (macrophages, platelets,
mast cells) [4]. Products of Lp-PLA2 can upregulate
expression of adhesion molecules, activate leucocytes
and recruit macrophages and monocytes into inflam-
matory areas [5-7]. Inhibition of Lp-PLA2 by the highly
potent and selective inhibitor darapladib effectively
ameliorated the clinical severity of atherosclerosis and
deceased inflammation in the plaque area in a swine
model [8]. Therefore, targeting of Lp-PLA2 has become
an attractive strategy for the treatment of atherosclerosis.
Lp-PLA2 is also called platelet-activating factor acetyl-
hydrolase (PAF-AH), as it can cleave platelet-activating
factor (PAF) in vitro by hydrolysis of the acetyl group
at the sn-2 position, producing lyso-PAF and acetate
[9,10]. PAF plays a prominent role in the pathogenesis of
IgE mediated allergic inflammation and anaphylaxis
(reviewed in [11-15]). Therapeutic targeting of PAF how-
ever did not affect asthma symptoms [16]. Nonetheless
because of its PAF catalyzing activity [17-22], inhibition
of PAF-AH/Lp-PLA2 raised the concern of an increased
predisposition to allergic inflammation or anaphylaxis.
Although the published direct evidence to support this
concern is limited, there were clinical associations
reported between low PAF-AH/Lp-PLA2, high plasma
PAF and increased incidents and severity of asthma
[23-26] and anaphylaxis [19]. A single nucleotide poly-
morphism of Val-279-Phe in the PAF-AH/Lp-PLA2
gene with functional deficiency was shown to be highlyprevalent in Japan (about 4% of the general Japanese
population) [27]. According to a 1999 study by Stafforini
et al. PAF-AH/Lp-PLA2 deficiency was increased in asth-
matics in comparison with healthy subjects in Japan with
the greatest asthma severity found in homozygous PAF-
AH/Lp-PLA2 deficient subjects [25]. In animal models of
lung injury and sepsis elevated PAF-AH/Lp-PLA2 levels
were reported to be associated with inhibitory effects dur-
ing the acute inflammatory process [28,29]. Exogenous ad-
ministration of PAF-AH/Lp-PLA2 reduced mortality [18]
and over-expression of PAF-AH/Lp-PLA2 attenuated in-
flammation in mouse models of sepsis [17,18,30] suggest-
ing that this enzyme may have protective effects against
inflammatory mechanisms involving PAF.
This suggestion was contested in a clinical study con-
ducted very similarly to that of Stafforini’s. In this work
Satoh and colleagues found no difference in the allele
frequency between asthmatic patients and healthy con-
trols and the V279F mutant allele prevalence was con-
sistent regardless of asthma type or severity of disease
[31]. In a more recent study Japanese patients under-
went a bronchoprovocation test with PAF showed no
difference in airway responsiveness whether they had the
V279F mutant allele or not [32]. Further, in human stud-
ies treatment with a recombinant PAF-AH/Lp-PLA2
preparation showed no sufficient efficacy in asthma or in
sepsis ([33] reviewed in [1]).
Based on these controversial data, the question
whether low circulating PAF-AH/Lp-PLA2 may predis-
pose to heightened inflammation and IgE-mediated al-
lergic immune responses remains to be clarified. The
aim of our study was to investigate whether genetic tar-
geting of PAF-AH/Lp-PLA2 would result in pro- or anti-
inflammatory changes following allergen exposure in a
murine model of allergic sensitization.
Methods
Mice
Wild type C57BL/6 mice (6 to 8 weeks old) were pur-
chased from the Jackson Laboratories (Bar Harbor, ME).
Wild-type mice and homozygous Lp-PLA2-/- mice have
been maintained in specific pathogen-free facilities at
the University of Pennsylvania. Mice were fed chow and
water ad libitum and were under a 12 hour daylight/dark
cycle. The University of Pennsylvania Institutional Animal
Care and Use Committee (IACUC) approved all protocols,
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the guidelines of the University of Pennsylvania IACUC.
The Lp-PLA2 targeting strategy
Standard gene targeting approaches were used to gener-
ate 129-C57BL/6J hybrid ES cells heterozygous for the
Lp-PLA2 primary targeted allele, which contains two
loxP sites flanking a neo cassette within intron 3 and an
additional loxP site within intron 2. 50 and 30 homology
arms (3240bp and 4496bp respectively) and the ‘floxed’
exon 3 region (872bp) were isolated by PCR from
C57BL/6J genomic DNA (Figure 1A). Homologous re-
combination in neomycin resistant ES cells was con-
firmed at the 50end by Southern blot analysis using
probes external to the homology arm (data not shown),
and at the 30 end by long range PCR using primers in-
ternal and external to the targeting vector. Two correctly
targeted ES cell clones were injected into Balb/c-derived
blastocysts, and resultant male chimaeras were crossed
with C57BL/6J females to produce mice heterozygousFigure 1 Lp-PLA2 targeting strategy and measurement of PAF-AH act
recombination in ES cells was used to generate ES cells heterozygous for t
the Lppla2 primary targeted allele with a germline Cre-deleter strain resulte
indicated as blue boxes; the neor selection cassette as a red box; loxP and
of the PCR-derived homology arms in relation to the genomic locus struct
Lp-PLA2-/- mice. PAF-AH activity in the serum of C57BL/6 wild type (WT) a
Mean±SEM; n=6-8.for the Lp-PLA2 primary targeted allele. These were
subsequently bred to a germline Cre- deleter strain
resulting in mice heterozygous for the Lp-PLA2 null
allele (Lp-PLA2n/+). Marker-assisted backcrossing was
then employed to achieve a genetic background >98%
C57BL/6J. Study populations were produced by breed-
ing the homozygous strains.
PAF acetyl hydrolase activity
This was performed as previously described [34]. Briefly,
Lp-PLA2 activity was measured using either 1-decanoyl-2-
(4-nitrophenylglutaryl) phosphate (DNGP) or [3H]PAF
(Cascade Biochemicals) as a substrate. All assays were per-
formed at 37°C in 50 mmol/L HEPES and 150 mmol/L
NaCl, pH 7.4. Serum samples (at different dilutions) were
added to 50 μmol/L DNGP in buffer at 37°C. The absorb-
ance increase was followed at 400 nm, using either a diode
array spectrophotometer (Hewlett-Packard) or a 96-well
plate reader (Molecular Devices, Tmax) running in kinetic
mode. Product was quantified using the publishedivity in mice. (A): Generation of Lp-PLA2-/- mice: Homologous
he Lp-PLA2 primary targeted allele. Breeding of mice heterozygous for
d in mice heterozygous for the Lp-PLA2 null allele. Lp-PLA2 exons are
FRT sites as yellow and green arrowheads respectively. The positions
ure are indicated by dotted lines. (B): PAF hydrolysis is defective in
nd Lp-PLA2-/- mice was measured as described. Data are expressed as
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-1·cm-1 [34]. For
PAF-AH activity, [3H]PAF and sample were incubated in a
final volume of 200 μL for 10 minutes at 37°C. The reac-
tion was stopped by vortexing with 600 μL of CHCl3/
MeOH (2:1), and the CHCl3 and aqueous layers were
separated by centrifugation. The aqueous layer was
removed (250 μL) and vortexed with 250 μL of CHCl3.
The aqueous layer was again removed and the [3H]acetate
determined by scintillation counting. Protein was deter-
mined using the Pierce bicinchonic acid assay kit, accord-
ing to the manufacturer's instructions. To determine the
inhibitory effect of SB-435495, the serum samples and the
compound were preincubated at 37°C for 10 minutes be-
fore running the enzyme assay as described above
(Figure 1B).
LPS/PAF treatment
Following experiments to determine the optimal dose and
time course, C57BL/6 wild type (WT) and Lp-PLA2-/-
mice (n=6-7 in each group) were administered 1 μg LPS
and 1 μg of a 1:1 mixture of PAF (C16) and PAF (C18) via
intra-tracheal instillation under light ketamine/xylazine
anesthesia. 24 hours later lung function measurements
were performed and bronchoalveolar lavage (BAL) was
obtained from each mice as described below.
Preparation of Aspergillus fumigatus (Af)-specific serum
for passive sensitization
Wild type male C57BL/6 mice (n=10) at 12-15 weeks of
age, were injected intraperitoneally (i.p.) with 20 μg Af
adsorbed on alum, on day 1 and 7 and then received
intranasal (i.n.) treatment with 30 μg Af on day 13 and
subsequently every other days to total 6 doses. Mice
were sacrificed 2 days after the last allergen treatment
and blood was obtained in vacutainers. Blood from naïve
mice (n=10) was obtained for naive serum. Serum sam-
ples were pooled, aliquoted and stored at -20ºC.
Total IgE was measured by a mouse IgE ELISA kit
(GenWay, San Diego CA) according to manufacturer’s
instructions. Af-specific immunoglobulin levels were
determined as previously described [35]. Serum (dilution
1:100) or undiluted BAL supernatant samples were
loaded from individual mice.
Mast cell culture and function assay
Mast cell function was assessed using bone-marrow
derived mast cells and hexosaminidase release in re-
sponse to sensitization with specific anti-Af serum or
anti-DNP IgE antibody (Sigma, St. Louis, MO). Bone
marrow was harvested from wild-type C57BL/6 mice
(The Jackson Laboratory, Bar Harbor, ME) and Lp-
PLA2-/- mice. Cells were then purified on ficoll-paque
(Amersham Biosciences, Sweden) and maintained for 3-
4 weeks in RPMI1640 medium supplied with 20 ng/mlmurine IL-3. Mast cells were characterized by morph-
ology under phase contrast microscope (Figure 2A upper
panels) and FACS analysis using antibodies against FcεRI
and CD117 (BD Pharmingen, Figure 2A lower panels).
The cells were sensitized with mouse serum containing
IgE against Af (1:100 dilution) for 12 hr and challenged
with 3 μg/ml Af for 2 hr. Anti-DNP IgE (2 μg/ml) and
DNP (10 μg/ml) were used as positive control. Cells
were either sensitized alone or challenged alone as nega-
tive controls. Hexosaminidase released from activated
cells was measured by reaction with 8 mM p-nitrophe-
nyl-N-acetyl-β-d-glucopyranoside (PNP-NAG, Sigma)
for 12 hours, optical density (OD) was measured on 405
nm spectermeter. Data was presented as fold increase
over naïve cell culture medium.
Passive allergic airway sensitization using Aspergillus
fumigatus (Af)-specific serum
This sensitization model is based on the effects of aller-
gen specific immunoglobulins and other mediators in
pooled serum of actively sensitized mice. Inflammation
is thought to be mediated by interactions between im-
munoglobulin IgE and the mast cell high affinity IgE re-
ceptor FcεR-I, leading to mast cell degranulation and
release of a variety of inflammatory mediators. To elicit
the IgE-mediated changes, 9-12 week-old male WT and
Lp-PLA2-/- mice were sensitized i.v. by anti-Af specific
serum on day 1, day 2 and day 3. Dose-response studies
determined that the optimal serum dilution to elicit the
expected inflammatory changes fell between 1:100 and
1:1000 (not shown). We used a dilution of 1:200
throughout the study. 30 μg Af was applied intranasally
to mice on day 5. Mice were studied 72 hours after Af
challenge. Negative control mice received naive serum
and/or were challenged with PBS.
Active allergic airway sensitization with Af
For active allergic sensitization, 9-12 week-old male
C57BL/6 wild-type and Lp-PLA2-/- mice were injected
intraperitoneally (i.p.) with 20 μg of Af pre-formulated
with alum (volume 1:1) on day 1 and 7 and then chal-
lenged intranasally (i.n.) with 30 μg Af on day 13. Mice
were studied on day 15.
Lung function measurements
Lung function was measured as described previously
[36-40]. Airway hyperresponsiveness to methacholine
(MCh) inhalation was assessed using the FlexiVent sys-
tem (Sireq, Montreal, Canada). This method is suitable
to measure lung resistance and dynamic compliance, the
most important physiological characteristics of the in-
flammatory airway response. Briefly, lung mechanics
were studied in tracheostomized mice under anesthesia
by intra-peritoneal injection of ketamine and xylazine.
A. B.
C. D. E.
Figure 2 Lp-PLA2 deficiency did not enhance the function of bone marrow-derived mast cells. (A): Bone marrow cells harvested from
C57BL/6 wild type (WT, white bars) and Lp-PLA2-/- (black bars) mice were cultured for 3-4 weeks in the presence of 20 ng/ml murine IL-3. Mast
cells were identified by phase contrast microscope (top panels) and FACS analysis using antibodies against FcεRI and CD117 (bottom panels).
(B): Cells were sensitized with pooled WT anti-Af serum (1:100 dilution) and challenged with 3 μg/ml Af in vitro (n=4, left panel). Hexosaminidase
release was measured in non-treated cells, cells treated with naïve serum alone or anti-Af serum alone (not shown); naïve serum+Af and anti-Af
serum+Af. Anti-DNP IgE (2 μg/ml) and DNP (25 μg/ml) treated cells were used as positive controls (n=4). Data presented as % of the total
β-hexosaminidase present in 0.1% Triton X-100 lysed cells. (C): Cells derived from wild-type or LP-PLA2-/- mice were sensitized with individual
anti-Af serum samples, derived from WT mice that received active sensitization (n=9-10). Cells then were challenged with 3 μg/ml Af. Median and
interquartile ranges. The assay was performed in triplicates (left panel). The right panel shows a correlation between Lp-PLA2 levels (as measured
by PAF-AH activity) and mast cell degranulating activity (hexosaminidase release) of 6 serum samples. Data are presented as ratio over naïve
serum control. (B-C): Released hexosaminidase in supernatant was measured by reaction with 8 mM p-nitrophenyl-N-acetyl-β-d-glucopyranoside
(PNP-NAG). Data calculated from the total β-hexosaminidase present in 0.1% Triton X-100 lysed cells.
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rate of 150 breaths/min and a positive end-expiratory
pressure of 2cm H2O by a computerized FlexiVent Sys-
tem. After mechanical ventilation for 2 min, a sinusoidal
1-Hz oscillation was applied to the tracheal tube. The
single-compartment model was fitted to these data by
multiple linear regression to calculate dynamic resist-
ance and compliance of the airway. At the end of lung
function measurement, BAL cells were collected for
cytospin preparation and differential cell counting. The
BAL supernatant was aliquoted and stored at -80°C.
Inflammatory profile
Lung inflammatory profile was assessed as described
previously in our laboratory [35,36,41-44]. To assess ac-
tivation of inflammatory cells, serum and BAL were
obtained at the end of experiments. Measurements of
cytokines/chemokines were performed using Searchlight
technology (Aushon Biosystems Inc, Billerica MA).Statistical analysis
The number of mice used in the study was determined by
standard power calculations using preliminary data and
our previous experience in these models. The number of
mice used in individual groups for statistical analysis is
stated in the figure legends. Results are presented as the
mean ± standard error (SE) of each group. Unless other-
wise stated, data were analyzed by two-way ANOVA fol-
lowed by a Bonferroni post-hoc test. A value of p < 0.05
was considered as statistically significant. All statistical
analyses were performed using Graphpad Prism software
(GraphPad Software Inc, La Jolla, CA).
Results and discussion
PAF-AH activity is reduced but not abolished by in vitro
treatment with high concentration of SB-435495 and in
Lp-PLA2-/- mice
To determine whether PAF-AH/Lp-PLA2 activity is
altered by the enzyme inhibitor SB-435495 in the mouse
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mice were investigated using a previously established
technique based on a modified hydrolysis assay [45].
This assay measures the enzyme product lyso-PAF.
The average serum PAF-AH activity was 38.1 and
9.3 nM/min/ml in naive WT and Lp-PLA2-/- mice,
respectively. Treatment of WT serum with 10μM of
SB-435495 (a saturating concentration used to com-
pletely abolish Lp-PLA2), reduced enzyme activity to
levels observed in serum from Lp-PLA2-/- mice lacking
a functional Lp-PLA2 gene (Figure 1A-B). In both WT
and Lp-PLA2-/- mice there was a significant residual
PAF-AH activity in the serum which was obviously not
attributable to Lp-PLA2. These findings suggest that
Lp-PLA2 may not be the exclusive PAF-cleaving enzyme.
Further, it is likely that the main mechanism of action of
this enzyme is not the cleavage of PAF. Additional sup-
port for this is provided by a recent study in which treat-
ment of mice with darapladib (an Lp-PLA2 inhibitor)
inhibited serum IL-6 levels but did not alter serum PAF
levels in a model of atherosclerosis [46]. Nonetheless,
in the serum of Lp-PLA2-/- mice PAF metabolism was
significantly reduced. The in vivo significance of the lack
of Lp-PLA2 has not been determined before in gene defi-
cient animals, therefore we next investigated the effects
of PAF treatment in these mice.
LPS+PAF-induced inflammatory cell influx and airway
hyperresponsiveness was similar between Lp-PLA2-/-
and WT mice
PAF has been implicated in inflammatory conditions via
diverse biological pathways both as an anti-inflammatory
[47] and as a proinflammatory [48] mediator. Studies in
mice and gerbils suggested that increased PAF levels and
decreased PAF-AH activity significantly contribute to se-
verity of inflammation in sepsis and that treatment with
recombinant PAF-AH inhibit the inflammatory changes
[48]. Results of human trials using recombinant PAF-
AH to treat sepsis were however controversial [33]. Fur-
ther, although PAF-AH/Lp-PLA2 can hydrolyze PAF
in vitro (Km value for Lp-PLA2 for PAF is >10μM), there
is little to no evidence that this enzyme is involved in
the metabolism of PAF in vivo (where PAF is active at
low nM levels). To investigate the role of PAF cleavage
in airway inflammation we generated PAF-AH/Lp-PLA2
deficient mice on a C57BL/6 background and used a
model of LPS/PAF inhalational treatment. The model
was established in wild type C57BL/6 mice that were
administered 1 μg LPS and a 1:1 mixture of PAF (C16)
and PAF (C18) via intra-tracheal instillation. When in-
stilled on its own PAF did not induce inflammatory
changes however it significantly enhanced the effects of
LPS on neutrophil influx (Figure 3A-B). Figure 3B shows
results from experiments performed to compare theeffects of PAF, LPS and the combination of the two in
order to establish the optimal doses and time course of
the inflammatory effect. The effects of PAF were time
and dose dependent with doses 5-10 μg being lethal
when combined with LPS (not shown). The greatest
changes (but no lethality) were induced by the 1 μg dose
24 hours after instillation. Measurements of lung resist-
ance, dynamic compliance and total and differential cell
counts at the 24 hour time point revealed that Lp-PLA2
deficiency did not enhance the PAF effects on airway
neutrophilia and hyperresponsiveness in this model
(Figure 3C-E). Figure 3E compares WT and Lp-PLA2-/-
mice treated with a combination of PAF and LPS in their
BAL cell counts. A higher neutrophil count (in compari-
son with Figure 3B) may reflect the effects of additional
lung injury due to the lung function measurements that
were performed in these mice upon methacholine chal-
lenges for approximately 1 hour before sacrificed.
These results indicated that lack of PAF-AH/Lp-PLA2
did not increase susceptibility to the effects of exogenously
administered PAF on LPS-induced airway neutrophilia
and hyperresponsiveness in the gene deficient mice. In
contrast to previous findings in animal models of sepsis
[18,48], the data presented here suggested no protective
role of PAF-AH/Lp-PLA2 in cellular inflammation.
Lp-PLA2 deficient bone marrow-derived mast cells
had similar morphology, FcεR-I expression and released
hexosaminidase to a similar degree to wild-type mast
cells in vitro
In addition to sepsis, PAF is a major player in allergic in-
flammation. Produced by activated mast cells during the
immediate allergic response, PAF is capable of amplifying
mast cell activation through the PAF receptor [49]. Mast
cells also produce Lp-PLA2 that was suggested to decrease
PAF and increase lysoPAF production in an autocrine/
paracrine fashion [50,51]. Lack of Lp-PLA2 was therefore
suggested to predispose to IgE-mediated mast cell de-
granulation, a hallmark of severe allergic reactions such as
anaphylaxis [52].
To study the effects of Lp-PLA2 deficiency in mast cell
differentiation and degranulation we used bone marrow-
derived cultures of mast cells from WT and Lp-PLA2-/-
mice. At the end of the culture period mast cells from
both strains of mice showed similar presence of granules
in cytoplasm and had similarly high expression of FcεRI,
the high affinity IgE receptor (Figure 2A). In comparison
with cells treated with either the antibody or the antigen
alone, mast cells after sensitization (with anti-Af serum
or anti-DNP IgE) followed by cross-linking (with Af or
DNP, respectively), released significant amounts of hexo-
saminidase, a granule product (Figure 2B). Our results
demonstrate an average of 50%: a 2.5 fold increase in β-
hexosaminidase release in response to Af when cells
were sensitized with anti-Af serum in comparison with
In vitro   -Hexosaminidase release by BMMCB.A.
C. Ex vivo effect of anti-Af sera
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Figure 3 LPS/PAF-induced inflammatory cell influx and airway hyperresponsiveness was comparable between Lp-PLA2-/- and WT mice.
(A-B): C57BL/6 mice were administered nothing (Naïve, white bars), saline (light grey bars), 1 μg LPS (hatched bars), 1 μg PAF (dotted bars) or
1 μg LPS+PAF (dark grey bars) via intra-tracheal instillation under light anesthesia. BAL was obtained 24 hours later. (A): Cytospin preparations of
the cell pellet were assessed under light microscope. Giemsa stained panels are showing representative BAL samples from PAF (left panel), LPS
(middle panel) and LPS+PAF (right panel) treated mice. (B): Differential cell count was performed using total cell counts and cytospin
preparations. Cells were identified as Macrophages (MP), eosinophils (EP), neutrophils (NP) and lymphocytes (LC). Data are presented as absolute
cell number of BAL (mean± SEM, n=6). (C-E): C57BL/6 wild type (WT, white circles) and LP-PLA2-/- (black circles) mice were administered 1 μg
LPS+PAF via intra-tracheal instillation under light anesthesia. Lung resistance (C) and lung dynamic compliance (D) were measured by FlexiVent
in response to increasing doses of MCh 24 hours after treatment. (E): BAL cell pellet was assessed and data are presented as absolute cell number
of BAL (individual data points [n=6-7] are shown with the median indicated by a horizontal line).
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when cells were sensitized with anti-DNP IgE in com-
parison with cells treated with DNP alone. This indicates
a significant degree of mast cell degranulation induced
by FcεR-I crosslinking. There was a trend towards
reduced degranulation by Lp-PLA2-/- mast cells when
stimulated with anti-DNP-IgE+DNP (Figure 2B left
panel). However the extent of hexosaminidase release in
response to sensitization with the pooled anti-Af serum
preparation and Af challenge (Figure 2B right panel) or
to the treatment with individual serum samples obtained
from mice in the active sensitization protocol followed
by Af challenge (Figure 2C), was similar. Thus, cells
from WT and PAF-AH/Lp-PLA2 deficient mice showed
similar morphology, expressed FcεR-I at the same level
and released hexosaminidase in response to IgE cross-
linking to a similar degree. These data indicate that lack
of Lp-PLA2 did not enhance mast cell function in vitro.
It is possible that gene knockout of Lp-PLA2/PAF-AH
activity in mice will not generate the same types ofimmune/inflammatory changes as those found in
humans. However, in a recent article by Dyer et al. it
was shown that both human and mouse eosinophils
degranulated in response to PAF or lysoPAF in a PAFR
independent manner suggesting that relevant proinflam-
matory actions maybe mediated by both PAF and its
PAF-AH induced metabolite. Thus, Lp-PLA2 may not
necessarily play a negative feedback role during mast
cell activation. Indeed, the degree of degranulation in
WT mast cells positively correlated with the extent of
PAF-AH/Lp-PLA2 expression in the serum used for
sensitization of these cells (Figure 2C right panel), sug-
gesting a possible enhancing rather than inhibitory effect
on this proinflammatory mast cell function.
Lp-PLA2 deficiency did not increase airway inflammation
and hyperresponsiveness after allergen challenge of
passively sensitized Lp-PLA2-/- mice
To investigate the role of Lp-PLA2 in IgE-mediated
mechanisms we used a passive sensitization method
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different dilutions of serum containing Af-specific anti-
bodies from 1:10 to 1:100,000 we were able to elicit in-
flammatory changes following Af challenge of the mice.
The optimal induction of airway hyperresponsiveness
occurred at serum dilution of 1:200 (data not shown).
Lung resistance and lung dynamic compliance were
measured by the FlexiVent technique in response to in-
creasing doses of inhaled methacholine. Lung resistance
(RL; Figure 4B) and dynamic compliance (not shown)
were not significantly different between WT and Lp-
PLA2-/- mice albeit a trend for attenuation was observed
in the latter.
Airway inflammation was further quantitated by asses-
sing cellular composition. The total cell count in the
BAL was significantly increased in sensitized and chal-
lenged mice compared to the ones that received either
serum+PBS or PBS+Af treatment. Although a slight de-
crease was observed in this group, Lp-PLA2 deficiency
did not result in significantly altered inflammatory cell
influx (macrophages, eosinophils, neutrophils, lympho-
cytes) into the BAL fluid (Figure 4C). Although the
question whether the presence and direct involvement
of mast cells could be demonstrated in airway inflamma-
tion in our mouse model in vivo is important, this
exceeded the limitations of this current study. Our
results nonetheless indicate that Lp-PLA2 deficiency didA.
B. C.
Figure 4 Lp-PLA2 deficiency did not increase airway inflammation an
sensitized Lp-PLA2-/- mice. (A): 9-12 week-old male C57/B6 wild-type an
(results using 1:200 are shown) containing IgE against Aspergillus fumigatus
μg Af on day 5. Lung responses were analyzed on day 6. Control mice rece
resistance was measured by FlexiVent in response to increasing doses of M
were assessed under light microscope. Differential cell count was performe
Cells were identified as macrophages (MP), eosinophils (EP), neutrophils (Nnot affect airway hyperresponsiveness and inflammatory
response in the passively sensitized mice suggesting that
mast cell degranulation and downstream pathologies
may not be significantly affected by lack of Lp-PLA2. We
next assessed whether Lp-PLA2 deficiency would impact
allergic immune responses and pulmonary function in
actively sensitized mice.
Lp-PLA2-/- mice had similar degree of airway inflam-
mation and hyperresponsiveness, circulating and local
IgE but attenuated IL-4 and IL-5 release in the BAL fluid
when compared with WT mice.
In order to confirm the results obtained by passive al-
lergic sensitization and further investigate the role of
IgE-mediated mechanisms in airway inflammation
in vivo we used active (intraperitoneal) sensitization fol-
lowed by intranasal allergen challenge with Af [38].
Wild-type and Lp-PLA2-/- mice received two injections
of Af/alum (Vol: 1:1) one week apart, and were treated
intranasally with Af 6 days after the second Af/alum in-
jection. Negative control mice received Af challenge
alone (Figure 5A). Sensitized and challenged mice had
marked inflammatory cell influx into the airways, predo-
minated by eosinophilic granulocytes, a hallmark charac-
teristic of the allergic airway response. Although there
was a trend towards an attenuated airway eosinophilia in
Lp-PLA2-/- mice in comparison with WT mice, this dif-
ference did not attain statistical significance (Figure 5B).d hyperresponsiveness after allergen challenge of passively
d Lp-PLA2-/- mice were sensitized i.v. by different dilutions of serum
(Af) on day 1, day 2 and day 3, then intranasally challenged with 30
ived naive serum and/or were challenged with PBS. (B): Lung
Ch. (C): BAL was obtained and cytospin preparations of the cell pellet
d using total cell counts and Giemsa-stained cytospin preparations.
P) and lymphocytes (LC). (Mean±SEM n=5-11).
A. B.
C. D.
Figure 5 Lp-PLA2 deficiency did not increase inflammatory cell influx and airway hyperresponsiveness after allergen challenge of
actively sensitized Lp-PLA2-/- mice. (A): 9-12 week-old male C57/B6 wild-type and Lp-PLA2-/- mice were i.p. injected with 20 μg Af
pre-formulated with alum (volume 1:1) on day 1 and 7, then intranasally challenged with 30 μg Af on day 13 and studied on day 14 or 15. Mice
received Af challenge alone were negative controls. (B): Macrophages, eosinophils, neutrophils, lymphocytes in BAL were counted after cytospin
preparations and Giemsa staining. Data are presented as absolute cell number of BAL (mean± sem, n=10-11). Lung resistance (C) and lung
dynamic compliance (D) were measured by FlexiVent in response to increasing doses of MCh.
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after Af challenge of sensitized mice (Figure 5C-D). The
greatest changes in lung function in comparison with
non-sensitized controls were measured 48 hours after
Af challenge but there were no significant differences
between the WT and Lp-PLA2-/- groups at either
time points. The top lung resistance values (6.00±0.73
v.s. 6.72±1.51 cmH2O.s/ml) and dynamic compliance
values (0.0097±0.002 v.s. 0.0118±0.002 ml/cmH2O) were
obtained in response to 100 mg/ml MCh from WT and
Lp-PLA2-/- mice, respectively.
Lung H&E staining confirmed airway inflammation
after Af challenge of sensitized mice with the inflamma-
tory infiltrates localized in the peribronchial and perivas-
cular area. Histological scoring revealed no significant
differences between WT and Lp-PLA2-/- mice. Control
unsensitized mice had only a few inflammatory cells
(Figure 6A-B).
To determine if lack of Lp-PLA2 predisposes to heigh-
tened IgE production, ELISA assay was performed
(Figure 6C-D). IgE in BAL and serum of mice sensitized
and challenged with Af was significantly increased but
there were no differences between WT and Lp-PLA2-/-
mice. Anti-Af specific (but not total) immunoglobulin pro-
portion (including IgG1, IgE) in the serum of sensitized/
challenged WT mice showed a very strong positive correl-
ation with the capacity of the serum to degranulate mastcells (r=0.702 and 0.841, respectively) as well as with the
serum Lp-PLA2 levels (PAF-AH activity, r=0.920 and
0.860). None of these correlations were observed in Lp-
PLA2-/- mice suggesting that presence of Lp-PLA2 may
regulate proinflammatory events leading to increased im-
munoglobulin production. It was somewhat unexpected
therefore that we found that Af-specific immunoglobulin
levels (IgE, IgG1 and IgG2a) were generally greater in the
allergen exposed Lp-PLA2-/- mice than in WT mice. The
underlying mechanisms and the immune regulatory role
of Lp-PLA2 in antigen presentation are currently investi-
gated in our lab.
Luminex assay of BAL fluid showed that Af challenge
of sensitized mice significantly increased IL-4, IL-5 IL-6
and eotaxin levels (Figure 6E-F). CCL17 (not shown)
was also significantly induced while the Th1 cytokines
IL-2, IFN-γ, TNF-α, and IL-17 (not shown) were pro-
duced at very low levels 48 hours after Af challenge of
sensitized mice. IL-4 the central cytokine in eliciting
the allergic airway changes correlated well with levels of
IL-5, eotaxin and IL-6 (Figure 6E). Interestingly, lack of
Lp-PLA2 did not increase expression of any of these
proinflammatory mediators. Instead, the Lp-PLA2 defi-
cient mice had attenuated release of IL-4 (81.5% decrease
from WT levels), IL-5 (77.8% decrease from WT levels;
p<0.05, n=7), eotaxin (10.6% decrease from WT levels)
and IL-6 (46.5% decrease from WT levels) (Figure 6F).
B. Histological scoringA. Histological sections (H & E)
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Figure 6 Lp-PLA2-/- mice had similar degree of airway inflammation, circulating and local IgE but attenuated IL-4 and IL-5 release in
the BAL fluid when compared with WT mice. (A): Representative photomicrographs of H&E stained sections from formalin fixed and paraffin
embedded lung tissue of each group. (B): Inflammation was semi-quantitatively assessed (median shown; n=3-11). The following inflammation
score was used: (0-0.5): no infiltrates, intact lung structure. (1-1.5): <10 inflammatory cells/field. (2-2.5): Peri-bronchial/peri-vascular infiltrates. (3-3.5):
peribronchial/vascular cuffing with parenchymal extensions. The entire tissue section was scored. (C-D): Total IgE and anti-Af specific IgE was
measured by ELISA from serum and BAL samples of either non-sensitized (n=3) or Af-sensitized (n=11-16) mice. All animals received a single Af
challenge. Maxisorp 96-well plates were used and IgE was detected by HRP-conjugated anti-mouse IgE. Data presented as ng/ml for total IgE
with group median (C) or OD450 nm with group median for anti-Af specific IgE (D). The measurements were performed in duplicates.
(D left panel): A strong positive correlation is shown between serum Lp-PLA2/PAF-AH levels (ratio over naïve serum ctr) and Af specific serum IgE
levels in WT mice (but not Lp-PLA2-/- mice, not shown), sensitized and challenged with Af. (E-F): Cytokine and chemokine levels in cell-free BAL
supernatant were measured by a Luminex assay. (E): Correlation of Th2-related mediators with IL-4 (on the y axis). The points represent log10
transformed individual values. (F): Cytokine profiles shown among 4 groups, n=3-7. Data are presented as mean ± SEM, pg/ml. Student’t test
*p<0.05.
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local responses were commensurate with the airway
hyperresponsiveness measurements and that Lp-PLA2
deficiency did not enhance the allergic inflammatory
changes. The significance and mechanisms behind the
reduced BAL Th2-type cytokine production in the
Lp-PLA2-/- mice will need further investigation. Systemic
expression of the Th2 cytokines including IL-4 in the
serum of mice was also studied using a bead based (CBA)
assay. Cytokine levels in the serum however appeared
to be very low indicating that levels of local cytokines
may better reflect the extent of allergic immune response
than those of in the systemic circulation. The finding ofreduced IL-4 and IL-5 levels without reduction of IgE
in the BAL fluid of the Lp-PLA2-/- mice is somewhat
unexpected. However, such discrepancy may be explained
by the complexity of the mechanisms leading to immuno-
globulin production and involving antigen presentation,
T cell-B cell interactions, B cell and plasma cell func-
tions. Each of these mechanisms can have multiple regu-
latory pathways that are not necessarily dependent on
Th2 cytokines. The role of Lp-PLA2 in these is virtually
unknown and should be studied further.
PAF is a potent agonist that is highly active in the nM
range. The fact that PAF-AH activity in serum was not
completely eliminated could account for the relatively
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http://respiratory-research.com/content/13/1/100little differences seen between the inflammatory responses
of Lp-PLA2-/- and WT mice. Lp-PLA2-/- mice show
approximately 10 nM/min/ml residual PAF-AH activity
in their serum, which may still be effective in models
of inflammation. Indeed, this is an important finding
because major criticism of clinical efforts to Lp-PLA2
antagonism was based on the fear from potential elim-
ination of PAF metabolism resulting in increased PAF
levels and susceptibility to and severity of allergic/
anaphylactic events [19]. We believe that the cleavage
of PAF is not the exclusive mechanism of action of
this enzyme and our presented study supports this
argument. Additional support for this is provided by a
recent study in which treatment of mice with darapla-
dib (an Lp-PLA2 inhibitor) inhibited serum IL-6 levels
but did not alter serum PAF levels in a model of athero-
sclerosis [46]. The residual PAF-AH activity in the
serum of LP-PLA2-/- mice indicates that PAF can be
cleaved via additional pathways and therefore suscepti-
bility to allergic inflammation may not be increased
by the targeting of Lp-PLA2. This is demonstrated by
our data showing that allergen induced inflammatory
changes are not enhanced when Lp-PLA2 is elimi-
nated in Lp-PLA2-/- mice.
There is limited knowledge on alternative PAF cleaving
enzymes but it was shown for example that PAF can be
degraded by an esterase secreted from group A strepto-
coccus [55], an approach that could be used in future
studies to verify the importance of PAF-related inflam-
matory pathways.Conclusions
This study investigated the effects of PAF-AH/Lp-PLA2
deficiency on IgE-mediated airway inflammation. We
hypothesized that targeting this enzyme will enhance
allergen-induced cellular inflammation involving PAF.
Our results indicate that lack of PAF-AH/Lp-PLA2 in
the serum of knock-out mice or inhibition of it with SB-
435495 significantly reduced but did not completely
abolish PAF hydrolyzing activity in vitro. PAF inhal-
ation enhanced LPS-induced airway inflammation in WT
and Lp-PLA2-/- mice to a similar extent. Sensitized
WT and Lp-PLA2-/- bone-marrow derived mast cells
matured similarly and released β-hexosaminidase upon
stimulation with allergen or IgE crosslinking to a compar-
able degree. Wild type and Lp-PLA2-/- mice responded
to passive or active allergic sensitization by significant
and equal airway inflammation and hyperresponsiveness
after Af challenge. There were no differences in the
amount of total IgE levels in the Af sensitized WT and
Lp-PLA2-/- mice.
Taken together, these results indicated that Lp-PLA2
deficiency does not increase local cell-mediated allergicimmune responses or airway hyperresponsiveness in
these models. Our study is the first in which absence of
PAF-AH/Lp-PLA2 is investigated in vivo using gene defi-
cient mice.
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